RxDoctor Payments Data
★ My doctorsLook up a doctor →

Jose Vazquez-Tanus

Cardiovascular Disease · Doral, FLNPI 1902916893

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $44,088 of the $53,981 with a category attached, or 81.7%. Merck accounts for 62.4% of it on its own, with 7 other manufacturers making up the rest. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,981in general payments, 2019–2025

Across 97 payments — averaging $556.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$34K
  • Eli Lilly$19K
  • Novartis$1K
  • Bayer$119
  • Edwards Lifesciences$101
  • E.r. Squibb & Sons, L.L.C.$41
  • plus $49 from 2 others
$2,630,532in research payments, 2019–2025

Across 198 payments — averaging $13,286 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$1.8M
  • Novartis$388K
  • Merck$137K
  • Eli Lilly$105K
  • Modernatx, Inc.$79K
  • AbbVie$42K
  • plus $47K from 5 others

What the payments were for

  • Consulting fees$4,8259%
  • Speaking & faculty fees$3,0206%
  • Travel & lodging$44,08882%
  • Food & beverage$2,0294%
  • Education$200%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck29$33,678
Eli Lilly52$18,642
Novartis10$1,351
Bayer1$119
Edwards Lifesciences1$101
E.r. Squibb & Sons, L.L.C.2$41
Boston Scientific1$31
Medtronic1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,981 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$62,008
EliquisApixaban82$57,597
EntrestoSacubitril/Valsartan57$45,944
XareltoRivaroxaban15$10,860
Candesartan Cilexetil154$10,211
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid51$5,527
Metoprolol Succinate342$4,661
Amlodipine-ValsartanAmlodipine Besylate/Valsartan79$3,823
Rosuvastatin Calcium299$2,519
ClopidogrelClopidogrel Bisulfate224$2,417
Atorvastatin Calcium236$2,192
Carvedilol270$2,171
ProgesteroneProgesterone, Micronized29$1,796
Nitroglycerin PatchNitroglycerin36$1,662
Omega-3 Acid Ethyl Esters27$1,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,351$45,94457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Doral

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →